文献速递遗传性与小管间质肾病

欧洲疑似遗传性肾病患者基因检测可及性调查

Access to Genetic Testing in Patients With Suspected Genetic Kidney Disease in Europe.
PubMed 文献 · Kidney Int Rep · 2026-09-08

该研究调查了39个欧洲国家240名儿科和成人肾脏科医生及临床遗传学家,评估疑似遗传性肾病基因检测的可及性与障碍。97%认为基因检测重要,但50%在日常实践中遇到障碍;非OECD国家障碍评分更高,缺乏外部资金和非OECD来源与障碍相关。

要点

  • 97%受访者认为基因检测对改善诊疗重要,但50%在日常实践中遇到障碍。
  • 非OECD国家障碍严重度评分中位数6.8(IQR 3.6),显著高于总体4.0(IQR 4)。
  • 多数国家层面障碍为缺乏明确专业指南和对检测后可保险性的担忧。

核心结论

  • 研究识别了欧洲层面及区域内需解决的基因检测障碍,并提出了促进疑似遗传性肾病患者公平诊疗的建议。

研究设计与样本

  • 调查240名儿科肾脏科医生、成人肾脏科医生和临床遗传学家,覆盖39个欧洲国家。
  • 使用实施研究整合框架(CFIR)评估国家、医院、个人和实施流程层面的障碍,并按地区分层分析。

主要发现

  • 总体97%认为基因检测是改善诊疗的重要工具,但50%在日常实践中遇到障碍。
  • 障碍严重度评分中位数4.0(IQR 4,量表1-10),非OECD国家为6.8(IQR 3.6),P < 0.001。
  • 医院层面障碍包括资源不足(成本、时间、技术设施和人员)及缺乏合格患者或工作流程方案。
  • 非紧急检测周转时间中位数12周(IQR 12),紧急检测3周(IQR 2)。
  • 障碍按地区排序从北欧最少,依次为西欧、南欧、东欧,非OECD国家最多;缺乏外部资金和非OECD来源与障碍相关。

关键数值与推荐

  • 总体障碍严重度评分中位数4.0(IQR 4,量表1-10)。
  • 非OECD国家障碍严重度评分中位数6.8(IQR 3.6),P < 0.001。
  • 非紧急基因检测周转时间中位数12周(IQR 12),紧急检测3周(IQR 2)。

临床怎么用

  • 肾脏科医生应关注基因检测的可及性障碍,尤其非OECD国家资源有限地区。
  • 可参考研究提出的建议,推动制定明确专业指南和优化医院检测流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A genetic diagnosis can transform care for patients with monogenic kidney disease-guiding treatment, prognosis, family-planning, and care for relatives. Despite technological advancements, nephrologists still experience barriers to implementing diagnostic genetic testing in daily practice. METHODS: We surveyed 240 pediatric nephrologists, adult nephrologists, and clinical geneticists across 39 European countries on the accessibility of and barriers to genetic testing for suspected genetic kidney disease. Using the Consolidated Framework for Implementation Research (CFIR) model, we assessed barriers at national, hospital, individual, and implementation-process levels. Results were stratified by region (North, East, South, West Europe, and non-Organization for Economic Cooperation and Development (OECD) countries). Binary logistic regression identified factors associated with barrier experience. RESULTS: Overall, 97% regarded genetic testing an important tool to improve care, yet 50% experienced barriers in daily practice. Median barrier severity score was 4.0 (interquartile range [IQR] 4, scale 1-10). Non-OECD countries showed higher scores (6.8 (IQR 3.6), P < 0.001). Most reported national-level barriers were lacking clear professional guidelines and concerns about posttest insurability. Hospital-level barriers included insufficient clinic's resources (costs, time, technical facilities, and staffing), missing protocols for eligible patients or workflow and turnaround time (nonurgent: 12 weeks [IQR 12], urgent: 3 weeks [IQR 2]). Ranking barriers by region revealed a gradient from fewest barriers in Northern Europe, followed by West, South, East, and most in non-OECD countries. Lack of external funding and non-OECD origin were associated with barriers. CONCLUSION: We identified barriers that must be addressed at a European level and within regions. We provide recommendations to promote equitable care for patients with suspected hereditary kidney disease in Europe.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Gosselink ME, Buining F, König J, et al. Access to Genetic Testing in Patients With Suspected Genetic Kidney Disease in Europe. Kidney Int Rep. 2026. PMID: 42921271. doi:10.1016/j.ekir.2026.107070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。